VRN101099

VRN101099 is a brain-penetrant, orally bioavailable, irreversible and highly selective small molecule inhibitor of HER2 (Receptor tyrosine-protein kinase erbB-2). It is being developed as a targeted therapy for patients with HER2-positive solid tumors—including breast cancer—with particular focus on those with brain metastases or resistance to existing therapies such as T-DXd. Preclinical studies have demonstrated robust anti-tumor activity in intracranial xenograft models and superior efficacy compared to other HER2-targeted agents like tucatinib and trastuzumab. The drug spares wild-type EGFR and is not a substrate of BCRP transporters, contributing to its high brain permeability. Its first-in-human Phase 1 clinical trial began in early 2025 for patients with advanced HER2-positive solid tumors who have exhausted standard treatment options[3][4][5][6][7].